"Chemokine CXCL13" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine that is chemotactic for B-LYMPHOCYTES. It has specificity for CXCR5 RECEPTORS.
| Descriptor ID |
D054382
|
| MeSH Number(s) |
D12.644.276.374.200.120.650 D12.776.467.374.200.120.650 D23.125.300.120.650 D23.469.200.120.650 D23.529.374.200.120.650
|
| Concept/Terms |
Chemokine CXCL13- Chemokine CXCL13
- CXCL13, Chemokine
- SCYB13 Chemokine
- Chemokine, SCYB13
- Chemokine (C-X-C Motif) Ligand 13 (B-Cell Chemoattractant)
- CXCL13 Chemokine
- Chemokine, CXCL13
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL13".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL13".
This graph shows the total number of publications written about "Chemokine CXCL13" by people in this website by year, and whether "Chemokine CXCL13" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CXCL13" by people in Profiles.
-
Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 04 01; 59(4):860-868.
-
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ß Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2018 09; 70(9):1470-1480.
-
Role of TFH Cells in Promoting T Helper 17-Induced Neuroinflammation. Front Immunol. 2018; 9:382.
-
Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjögren's syndrome-like disease. Oral Dis. 2011 Nov; 17(8):801-7.